- Home
- SRTS
as of 12-23-2025 9:42am EST
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | BOCA RATON |
| Market Cap: | 67.5M | IPO Year: | 2016 |
| Target Price: | $8.00 | AVG Volume (30 days): | 59.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.03 - $9.08 | Next Earning Date: | 02-04-2026 |
| Revenue: | $35,609,000 | Revenue Growth: | -13.80% |
| Revenue Growth (this year): | -23.91% | Revenue Growth (next year): | 27.75% |
AI-Powered SRTS Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Sensus Healthcare Inc. (SRTS)
Director
Avg Cost/Share
$3.93
Shares
7,000
Total Value
$27,510.00
Owned After
140,113
SEC Form 4
PRESIDENT AND GENERAL COUNSEL
Avg Cost/Share
$3.80
Shares
1,000
Total Value
$3,800.00
Owned After
118,839
SEC Form 4
CHIEF EXECUTIVE OFFICER
Avg Cost/Share
$4.03
Shares
25,000
Total Value
$100,750.00
Owned After
1,200,293
SEC Form 4
Director
Avg Cost/Share
$4.50
Shares
2,500
Total Value
$11,250.00
Owned After
140,113
SEC Form 4
PRESIDENT AND GENERAL COUNSEL
Avg Cost/Share
$4.26
Shares
1,000
Total Value
$4,260.00
Owned After
118,839
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Sachetta Eric | SRTS | Director | Nov 21, 2025 | Buy | $3.93 | 7,000 | $27,510.00 | 140,113 | |
| Sardano Michael | SRTS | PRESIDENT AND GENERAL COUNSEL | Nov 18, 2025 | Buy | $3.80 | 1,000 | $3,800.00 | 118,839 | |
| Sardano Joseph C | SRTS | CHIEF EXECUTIVE OFFICER | Nov 18, 2025 | Buy | $4.03 | 25,000 | $100,750.00 | 1,200,293 | |
| Sachetta Eric | SRTS | Director | Nov 13, 2025 | Buy | $4.50 | 2,500 | $11,250.00 | 140,113 | |
| Sardano Michael | SRTS | PRESIDENT AND GENERAL COUNSEL | Nov 11, 2025 | Buy | $4.26 | 1,000 | $4,260.00 | 118,839 |
Compare SRTS vs Leading Stocks
See how SRTS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SRTS Sensus Healthcare Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.